1. Home
  2. ACM vs RDY Comparison

ACM vs RDY Comparison

Compare ACM & RDY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AECOM

ACM

AECOM

HOLD

Current Price

$80.29

Market Cap

11.2B

ML Signal

HOLD

Logo Dr. Reddy's Laboratories Ltd

RDY

Dr. Reddy's Laboratories Ltd

HOLD

Current Price

$13.65

Market Cap

11.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACM
RDY
Founded
1980
1984
Country
United States
India
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
11.2B
11.6B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
ACM
RDY
Price
$80.29
$13.65
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
10
1
Target Price
$131.40
$16.90
AVG Volume (30 Days)
935.1K
2.3M
Earning Date
05-11-2026
05-12-2026
Dividend Yield
1.54%
0.53%
EPS Growth
42.71
N/A
EPS
0.56
N/A
Revenue
$16,139,622,000.00
N/A
Revenue This Year
N/A
$7.72
Revenue Next Year
$6.06
$3.50
P/E Ratio
$143.34
$18.67
Revenue Growth
0.21
N/A
52 Week Low
$79.01
$12.77
52 Week High
$135.52
$16.17

Technical Indicators

Market Signals
Indicator
ACM
RDY
Relative Strength Index (RSI) 32.71 54.18
Support Level N/A $12.93
Resistance Level $87.66 $13.96
Average True Range (ATR) 2.32 0.27
MACD -0.19 0.07
Stochastic Oscillator 15.91 82.55

Price Performance

Historical Comparison
ACM
RDY

About ACM AECOM

Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets including water, transportation, and environment. Based in Dallas, Aecom employs 51,000. The company generated $16.1 billion in sales in fiscal 2025.

About RDY Dr. Reddy's Laboratories Ltd

Dr. Reddy's is one of the largest generic drug manufacturers in the world. It has a significant presence in North America, a region that makes up roughly half of its generics sales, and it services India (about 20% of its generics sales), Russia (10%), and certain European and Latin American countries. Beyond simple generics, Dr. Reddy's also has a solid portfolio of injectables which make up 25% of its North America sales. In branded generic markets like India, Dr. Reddy's has established a compelling presence with its strong brand name and earned a top five spot in key therapeutic areas including oncology and gastroenterology. Dr. Reddy's also has an active pharmaceutical ingredient business that manufactures over 150 APIs and sells in over 75 countries.

Share on Social Networks: